Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Study data from C.J. Wheeler and co-authors update knowledge of immunization
July 1st, 2009
"DCVax (R)-Brain (Northwest Biotherapeutics, Inc., Bethesda, MD, USA) is a personalized treatment for brain tumors. Its approach of administering autologous tumor antigen-bearing dendritic cells (DCs) has garnered hope for more effective and less toxic therapy for patients with malignant brain tumors including glioblastoma multiforme (GBM)," scientists in the United States report. "DCVax-Brain composition and efficacy are not fully disclosed, although sponsors claim it is poised to critically test clinical DC vaccine efficacy in GBM patients. This review examines the efficacy of DC vaccine therapy in treating GBM patients. Review question: To determine if the approach...
Source: Vaccine Weekly (2009-07-01)
|
